Skip to main content

GSK 6-K

GSK plc (GSK)

6-K 2026-03-09 For: 2026-03-09
View Original
Added on April 10, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 9 March 2026, London UK

Board Committee Change

GSK plc today announces the following change to its Board committee membership with effect from 9 March 2026:

Elizabeth McKee Anderson has been appointed as a member of the Corporate Responsibility Committee. This appointment is in addition to her membership of the Audit & Risk and Remuneration committees.

V A Whyte

Company Secretary

9 March 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc
(Registrant)
Date:<br>March 09, 2026
By:/s/ VICTORIA<br>WHYTE<br><br>--------------------------
Victoria Whyte
Authorised<br>Signatory for and on
behalf<br>of GSK plc